11762 related articles for article (PubMed ID: 10338155)
21. Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
Duraffour S; Snoeck R; Krecmerová M; van Den Oord J; De Vos R; Holy A; Crance JM; Garin D; De Clercq E; Andrei G
Antimicrob Agents Chemother; 2007 Dec; 51(12):4410-9. PubMed ID: 17893157
[TBL] [Abstract][Full Text] [Related]
22. Selective inhibition of human papillomavirus-induced cell proliferation by (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine.
Johnson JA; Gangemi JD
Antimicrob Agents Chemother; 1999 May; 43(5):1198-205. PubMed ID: 10223936
[TBL] [Abstract][Full Text] [Related]
23. Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro.
Neyts J; Snoeck R; Balzarini J; De Clercq E
Antiviral Res; 1991 Jul; 16(1):41-52. PubMed ID: 1663729
[TBL] [Abstract][Full Text] [Related]
24. Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG).
Neyts J; Snoeck R; Schols D; Balzarini J; De Clercq E
Virology; 1990 Nov; 179(1):41-50. PubMed ID: 2171213
[TBL] [Abstract][Full Text] [Related]
25. In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet.
Garré B; van der Meulen K; Nugent J; Neyts J; Croubels S; De Backer P; Nauwynck H
Vet Microbiol; 2007 May; 122(1-2):43-51. PubMed ID: 17276631
[TBL] [Abstract][Full Text] [Related]
26. Comparison of antiviral compounds against human herpesvirus 6 and 7.
Yoshida M; Yamada M; Tsukazaki T; Chatterjee S; Lakeman FD; Nii S; Whitley RJ
Antiviral Res; 1998 Dec; 40(1-2):73-84. PubMed ID: 9864048
[TBL] [Abstract][Full Text] [Related]
27. Antiviral activity of anti-cytomegalovirus agents (HPMPC, HPMPA) assessed by a flow cytometric method and DNA hybridization technique.
Snoeck R; Schols D; Andrei G; Neyts J; De Clercq E
Antiviral Res; 1991 Jul; 16(1):1-9. PubMed ID: 1663725
[TBL] [Abstract][Full Text] [Related]
28. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge.
De Clercq E
Biochem Pharmacol; 2007 Apr; 73(7):911-22. PubMed ID: 17045247
[TBL] [Abstract][Full Text] [Related]
29. Comparative activity of various compounds against clinical strains of herpes simplex virus.
Andrei G; Snoeck R; Goubau P; Desmyter J; De Clercq E
Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):143-51. PubMed ID: 1327785
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication.
Keith KA; Hitchcock MJ; Lee WA; Holý A; Kern ER
Antimicrob Agents Chemother; 2003 Jul; 47(7):2193-8. PubMed ID: 12821467
[TBL] [Abstract][Full Text] [Related]
31. Cidofovir in the treatment of HPV-associated lesions.
Snoeck R; Andrei G; De Clercq E
Verh K Acad Geneeskd Belg; 2001; 63(2):93-120, discussion 120-2. PubMed ID: 11436421
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of action of acyclic nucleoside phosphonates against herpes virus replication.
Neyts J; De Clercq E
Biochem Pharmacol; 1994 Jan; 47(1):39-41. PubMed ID: 8311844
[TBL] [Abstract][Full Text] [Related]
33. Prevention and inhibition of nasopharyngeal carcinoma growth by antiviral phosphonated nucleoside analogs.
Murono S; Raab-Traub N; Pagano JS
Cancer Res; 2001 Nov; 61(21):7875-7. PubMed ID: 11691806
[TBL] [Abstract][Full Text] [Related]
34. Antiviral activity of Cidofovir on a naturally human papillomavirus-16 infected squamous cell carcinoma of the head and neck (SCCHN) cell line improves radiation sensitivity.
Sirianni N; Wang J; Ferris RL
Oral Oncol; 2005 Apr; 41(4):423-8. PubMed ID: 15792615
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir.
Liekens S; Neyts J; De Clercq E; Verbeken E; Ribatti D; Presta M
Cancer Res; 2001 Jul; 61(13):5057-64. PubMed ID: 11431341
[TBL] [Abstract][Full Text] [Related]
36. Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs.
Li SB; Yang ZH; Feng JS; Fong CK; Lucia HL; Hsiung GD
Antiviral Res; 1990 May; 13(5):237-52. PubMed ID: 2168690
[TBL] [Abstract][Full Text] [Related]
37. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) inhibits HIV-1 replication in epithelial cells, but not T-lymphocytes.
Srinivas RV; Connely M; Fridland A
Antiviral Res; 1997 Jun; 35(1):23-7. PubMed ID: 9224958
[TBL] [Abstract][Full Text] [Related]
38. In vivo anti-papillomavirus activity of nucleoside analogues including cidofovir on CRPV-induced rabbit papillomas.
Christensen ND; Pickel MD; Budgeon LR; Kreider JW
Antiviral Res; 2000 Nov; 48(2):131-42. PubMed ID: 11114415
[TBL] [Abstract][Full Text] [Related]
39. 9-(2-Phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine (cpr-PMEDAP) as a prodrug of 9-(2-phosphonylmethoxyethyl)guanine (PMEG).
Compton ML; Toole JJ; Paborsky LR
Biochem Pharmacol; 1999 Aug; 58(4):709-14. PubMed ID: 10413310
[TBL] [Abstract][Full Text] [Related]
40. In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA.
Dal Pozzo F; Andrei G; Lebeau I; Beadle JR; Hostetler KY; De Clercq E; Snoeck R
Antiviral Res; 2007 Jul; 75(1):52-7. PubMed ID: 17184854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
